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Background and aims: Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common causes
of end-stage renal disease (ESRD). The most important cause of death among ADPKD patients is cardiovascular
(CV). The aim of this study was to examine the prognostic signiﬁcance of arterial stiffness on CV and renal outcomes
in ADPKD. Methods: A total of 55 patients with ADPKD were examined. Pulse wave velocity was determined and
stiffness index (SIDVP) was calculated. Combined primary endpoints (CV and renal) were major CV events
(myocardial infarction, stroke, and CV intervention) as CV endpoints, and attaining of ESRD or start of renal
replacement therapy as renal endpoints. Secondary endpoints were CV or renal endpoints separately. Results: The
mean age of those 55 ADPKD patients was 45± 12 years, 21 patients were male. The average value of the SIDVP was
11.11± 2.22 m/s. The patients were divided into two groups by the cutoff value of 11 m/s of SIDVP and then
outcomes were analyzed. In the higher arterial stiffness group (SIDVP> 11 m/s), occurrence of combined primary
endpoint (CV and renal) was signiﬁcantly higher than in the group with more elastic arteries (p= 0.033).
A statistically signiﬁcant difference was found in the renal endpoints (p= 0.018), but not in the CV endpoints
(p= 0.952) between the two groups. Conclusions: Increased arterial stiffness predicts the onset of ESRD in ADPDK.
Assessment of SIDVP appears to be a useful method for estimating the renal and CV prognosis in ADPKD.
Keywords: arterial stiffness, chronic kidney disease, autosomal-dominant polycystic kidney disease, renal
function, renal prognosis
Introduction
Autosomal-dominant polycystic kidney disease (ADPKD) is the most common hereditary
chronic kidney disease (CKD) with the prevalence of 1/400–1,000 live births (45). The
majority of cases show autosomal-xdominant inheritance. Mutations of two genes, polycystin
1 (PC1) and polycystin 2 (PC2), are responsible for development of the disease; however, the
precise pathogenic mechanism remains unknown (20). The mutant PC1 and PC2 proteins
modify the function of renal tubular cells. As a result, epithelial cell proliferation segmentally
develops in the renal tubuli, and the tubulointerstitial matrix may be disorganized leading to
the formation of growing cysts of various sizes. The clinical picture of ADPKD is
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characterized by the slow enlargement of the renal cysts, which gradually compress the
normal kidney parenchyma, and thus the disease slowly progresses into end-stage renal
disease (ESRD). The formation and enlargement of kidney cysts usually coexist with
extrarenal CV manifestations, including intra- and extracranial aneurysms, heart valvular
defects, and increased carotid intima-media thickness (11, 12, 23).
It is widely accepted that vascular dysfunction is common in ADPKD and CV
complications are mostly responsible for the increased mortality of ADPKD patients
(14, 41). More than 80% of CV complications are associated with dysfunction and disorders
of the arteries (15) and one of the greatest contributors to CV dysfunction is stiffening of the
large elastic arteries (25).
The aim of this study was to determine vascular function and to evaluate the prognostic
signiﬁcance of arterial stiffness on renal function and CV events in ADPKD patients. We
examined whether increased arterial stiffness could be an independent predictor of major CV
events (myocardial infarction, stroke, revascularization, and cardiac death) or ESRD. We also
purposed to determine the prognostic cutoff arterial stiffness value by photoplethysmogra-
phy. Such data are lacking in the literature as arterial stiffness has not yet been assessed with
photoplethysmography in renal patients.
Methods
Participants
This study was started between April 2007 and December 2008 at the 2nd Department of
Internal Medicine and Nephrological Centre, University of Pécs with 60 patients who had
ADPKD. Local ethics committee approved the clinical study protocol (no. 3170/2008) and
written informed consents were obtained from all participants. The diagnosis of ADPKD was
made on the basis of clinical picture, physical examination, and the typical abdominal
ultrasound morphology. Exclusion criteria were severe clinical conditions (NYHA III-IV
heart failure, stroke and myocardial infarction within 3 months, uncontrolled cardiac
arrhythmia, malignant disease requiring active treatment, and ongoing infection with fever).
Patients with ESRD (CKD stage 5), renal replacement therapy, or kidney transplant were also
excluded from the study.
Clinical assessment
The modiﬁcation of diet in renal disease formula was used to determine renal function
[estimated glomerular ﬁltration rate (eGFR): ml/min/1.73 m2]. The classical CV risk factors,
such as hypertension, carbohydrate metabolism disorders (diabetes mellitus, impaired
glucose tolerance, and elevated fasting glucose level), obesity, lipid abnormalities, and
smoking, were also assessed at the ﬁrst visit. The World Health Organization criteria were
used for the deﬁnition of the metabolic syndrome. All enrolled patients were regularly
examined at 3- to 6-month intervals (or more often if necessary). At visits, any adverse events
since the last visit were interviewed, physical status was determined, and detailed laboratory
tests were performed. Blood pressure was calculated as the average of three measurements
after 10 min resting. Complete CV examinations (echocardiogaphy, ergometry, coronaro-
graphy, etc.) were carried out when it seemed to be necessary based on the patients’
complaints. Abdominal ultrasound was performed on all patients every 2 years.
On follow-up, ﬁve patients did not attend the check-ups, thus their data were not
analyzed.
146 Sági et al.
Physiology International (Acta Physiologica Hungarica) 105, 2018
Determination of vascular stiffness
We used the ﬁnger photoplethysmography method by the Pulse Trace System (Micro
Medical Ltd., Rochester, UK) to assess pulse wave velocity (PWV) as described earlier
(21, 22). This method allows the determination of the stiffness index (SI), which can be
derived from the digital volume pulse (DVP), and is reﬂected as SIDVP. Brieﬂy, DVP includes
two distinct waves during the cardiac cycle: an early systolic one that originates from the
pressure wave at the time of the left ventricular ejection, which could be measured in the
ﬁnger artery, followed by a second peak due to a reﬂected wave from more peripheral
segments, which usually form the aortic bifurcation. The SI is derived from body height
relative to the time difference between the forward and reﬂected pulse waves: SIDVP (m/s) =
height/Δt. The recorded pulse curve proﬁle is principally determined by the PWV of the large
arteries (8, 18). Based on literature data, the results of the method used here correlate with
those of other methods, such as the central aortic PWV (34). Higher SIDVP values indicate
increased vascular stiffness (2, 6, 33).
Patients were allowed to take their regular medications. The participants were asked not
to smoke and not to drink coffee on the day of the examination. All subjects were examined in
supine position after at least 10 min of resting. Single waveform was obtained by averaging
the DVP proﬁles for 30 s. To enhance the accuracy of the SIDVP measurements, ﬁve period
samples were taken and the upper and lower values of DVP were deleted. The remaining
three values were averaged and used for further analysis, including the variability test. All
measurements were performed in the morning hours between 9 and 11 a.m., thereby
eliminating confounding effects of the circadian variability.
The data analyser was unaware of clinical information of the patients.
Statistical analysis
All results are expressed as mean± SD for variables with normal distribution unless
otherwise speciﬁed. Survival was examined by Mantel–Cox log-rank test. Cox regression
analysis was used to evaluate the effects of factors on survival. Receiver operating
characteristic (ROC) analysis was performed to determine the SI value that separates the
two groups most appropriately for the outcome. Multivariate analysis was used to explore the
factors that inﬂuence CV events and impaired renal function.
On the basis of the average SI value, the patients were divided into two groups at the
cutoff point of 11 m/s, and the outcome of the two groups was analyzed and compared. The
combined primary endpoint was the combination of myocardial infarction, stroke, or CV
intervention as the CV endpoints or ESRD (CKD stage 5) and start of renal replacement
therapy as the renal endpoints. Subsequently, CV and renal endpoints were analyzed
separately as secondary endpoints.
Statistical analysis was performed using the SPSS software version 22.0, and p value of
<0.05 was considered as statistically signiﬁcant.
Results
A total of 55 ADPKD patients (21 males, mean age: 45± 12 years) were analyzed. Patients
were followed up for an average of 63± 32 months. The clinical characteristics and
occurrence of CV risk factors are summarized in Table I. The mean SIDVP value was
11.11± 2.22 m/s and the patients were divided into two groups at this cutoff value. Table I
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shows the characteristic features of all patients and in the two subgroups. Patients with
increased SIDVP (SIDVP> 11 m/s) were signiﬁcantly older (p= 0.002) and their renal function
was signiﬁcantly worse (p= 0.013).
The occurrence of primary combined and secondary endpoints in the two subgroups are
shown in Table II and Fig. 1A and B. Figure 1A shows that probability of the combined
primary endpoint (CV and renal) was signiﬁcantly higher in the subgroup with increased
stiffness (SIDVP > 11 m/s) compared to the group with more elastic arteries (SIDVP ≤ 11 m/s),
(χ2: 4.571; p= 0.033). For the CV endpoint, there was no signiﬁcant difference in the
outcome between the two subgroups (χ2: 0.004; p= 0.952) (data not shown). In contrast,
probability of the renal endpoint was signiﬁcantly higher with increased arterial stiffness
(χ2: 5.591; p= 0.018) (Fig. 1B).
We performed ROC analysis to determine the SI value obtained through the method
ﬁnger photoplethysmography, which most appropriately separates the two subgroups for any
outcome, and this SIDVP value was 10.66 m/s.
The Cox regression model showed that every 1 m/s increase of the SI increased the prob-
ability of the cumulative endpoint by 18.7%[odds ratio: 1.187 (CI: 1.001–1.408); p= 0.048].
Table I. Baseline characteristics of ADPKD patients
ADPKD patients
(n= 55)
SI≤ 11 m/s
(n= 27)
SI> 11 m/s
(n= 28) p value
Male/female (n) 21/34 8/19 13/15 0.103
Age (year) 45± 12 41± 10* 49± 11* 0.002
Follow-up time (month) 63± 32 67± 31 58± 33 0.156
Duration of ADPKD (year) 13.2± 9.2 12.8± 8.5 13.7± 9.7 0.364
eGFR (ml/min/1.73 m2) 72± 36 82± 37** 61± 31** 0.013
Stiffness index (m/s) 11.11± 2.22 9.44± 1.41*** 12.71± 1.56*** 0.001
Metabolic syndrome components
Obesity [n (%)] 22 (40) 11 (37) 11 (39) 0.457
BMI (kg/m2) 28.5 28.4 28.5 0.453
Carbohydrate metabolic
disorders [n (%)]
13 (24) 5 (18) 8 (28) 0.194
Dyslipidemia [n (%)] 26 (47) 13 (48) 13 (46) 0.450
Hypertension [n (%)] 46 (84) 21 (78) 25 (89) 0.128
Metabolic syndrome [n (%)] 13 (24) 5 (18) 8 (28) 0.194
Smoking [n (%)] 20 (36) 9 (33) 11 (39) 0.326
ACEI/ARB therapy [n (%)] 46 (84) 21 (78) 25 (89) 0.128
SIDVP: stiffness index; ADPKD: autosomal-dominant polycystic kidney disease; eGFR: estimated glomerular ﬁltration
rate; BMI: bodymass index; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin-receptor blocking agent.
*p= 0.002.
**p= 0.013.
***p= 0.001
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Multivariate analysis of variance was used to explore those factors that could predict CV
events and renal functional decline, independently of other parameters; in this model, only
baseline renal function (eGFR) has proved to be an independent prognostic factor for the
combined CV and renal outcomes (Table III; p< 0.001).
There were signiﬁcantly more CV events in the group of patients with metabolic
syndrome than in the group of patients without it (χ2: 6.246; p= 0.012) (Fig. 2). SIDVP of the
patients with metabolic syndrome was signiﬁcantly higher than those of patients without it
(12.1± 2.3 m/s vs. 10.8± 2.1 m/s; p= 0.036). Cox regression analysis showed that metabolic
syndrome was an independent predictor for CV endpoints (p= 0.022), but not for the
combined primary and secondary renal endpoints (Table IV).
Discussion
We have found that increased arterial stiffness was an independent prognostic factor for the
combined CV and renal outcomes in ADPKD patients. Arterial stiffness measured by Pulse
Trace System appears as a useful and applicable method for estimating the renal and CV
prognosis in ADPKD.
Increased arterial stiffness in CKD
It was demonstrated several years ago that arterial stiffness is markedly increased in ESRD (9,
13, 17, 28, 29, 44). Recent data indicated that arterial stiffening is increased in CKD, even in
patients with mild to moderate loss of renal function or in the presence of microalbuminuria
(7, 46, 47, 50).
The pathophysiological mechanism of increased arterial stiffness observed in CKD is
not entirely deﬁned. Several putative mechanisms have been implicated, including chronic
hypervolemia, chronic microinﬂammation, lipid peroxidation, suppression of the nitric oxide
system, excessive sympathetic activity, activation of the renin–angiotensin–aldosterone
system (RAAS), as well as increased mechanical stress due to either hypertension or the
arterial wall calciﬁcation (19, 30).
Increased arterial stiffness and ADPKD
ADPKD patients exhibit vascular dysfunction as increased arterial stiffness and this stiffness
is evident very early in the course of ADPKD even in patients with normal renal function
(5, 40). In a previous cross-sectional study, we showed that arterial stiffness is increased as
the renal function declined in a homogeneous group of CKD patients with IgAN (22).
Table II. Occurrence of primary and secondary end points in the ADPKD patients
Secondary endpoints
Patients number (n)
Primary, combined
endpoints [n (%)] Renal [n (%)]
Cardiovascular
[n (%)]
SIDVP≤ 11 m/s 27 12 (44) 9 (33) 3 (11)
SIDVP> 11 m/s 28 18 (64) 12 (43) 6 (21)
Total events [n (%)] 30 (53) 21 (38) 9 (16)
SIDVP: stiffness index; ADPKD: autosomal dominant polycystic kidney disease
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Moreover, we concluded that the etiology of CKD may also affect the degree of arterial
stiffness by comparing IgAN and ADPKD patients, as our ﬁndings have shown that arterial
stiffness develops earlier and the progression is more rapid in ADPKD than in IgAN patients
with comparable renal function (22).
Cumulative survival
p=0.033
SIDVP
SIDVP > 11 m/s
≤ 11 m/s
≤ 11 m/s
Time to first event or end of follow-up (month)
Time to first event or end of follow-up (month)
Cumulative survival
p=0.018
SIDVP
SIDVP > 11 m/s
(a)
(b)
Fig. 1. (A) Primary,
combined endpoints in
ADPKD patients with
SIDVP> 11 m/s versus
SIDVP≤ 11 m/s.
(B) Secondary renal
endpoints in ADPKD
patients with
SIDVP> 11 m/s versus
SIDVP≤ 11 m/s
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The pathomechanism of the vascular lesions in ADPKD
The pathomechanism of the premature CV lesions in ADPKD is not fully understood;
however, several factors could be involved in the development of CV abnormalities in
ADPKD. Nauli et al. (37) implied that vascular dysfunction in ADPKD may be a
Table III. The prognostic role of each parameter in association with combined primary endpoints
(multivariate analysis)
B SE Wald df p Exp (B)
SIDVP −0.049 0.114 0.182 1 0.670 0.952
Age −0.017 0.022 0.603 1 0.437 0.983
eGFR −0.055 0.010 28.208 1 <0.001 0.946
Gender −0.884 0.455 3.786 1 0.052 0.413
Hypertension −0.924 0.896 1.063 1 0.303 0.397
Carbohydrate
metabolic
disorder
0.016 0.507 0.001 1 0.975 1.016
Dyslipidemia 0.810 0.528 2.350 1 0.125 2.247
Obesity −0.686 0.550 1.558 1 0.212 0.504
B: beta coefﬁcient; SE: standard error; eGFR: estimated glomerular ﬁltration rate
ADPKD Metabolic syndrome 
–
ADPKD Metabolic syndrome +
Time to first event or end of follow-up (month)
p=0.012
Cumulative survival
Fig. 2. Secondary
cardiovascular endpoints
in ADPKD patients with
metabolic syndrome
versus without metabolic
syndrome
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consequence of an inherited disorder of endothelial cilia. The disorder of the primary cilium,
which covers the internal surface of endothelial cells of the blood vessels, may trigger a
biochemical cascade mechanism leading to decreased nitric monoxide (NO) availability and
endothelial dysfunction (1, 37). As a result, vascular remodeling by the cilium dysgenesis
may develop due to impaired cell differentiation and altered connective tissue structure, thus
leading to increased vascular rigidity. Consistently, the plasma concentration of NO was
lower in ADPKD (16, 48, 49).
In another hypothesis, the cause of vascular complications in ADPKD could be
explained by the polycystic kidney itself. Brieﬂy, enlarged kidney cysts causing structural
damage of the nephrons and distortion of the normal kidney structure lead to intrarenal
ischemia that activates the RAAS system, which has important roles in CV remodeling.
Activation of RAAS occurs very early in ADPKD patients, in both adults and children, often
preceding the onset hypertension and renal failure (36, 39, 45). Hyperplasia of the renin-
producing cells in the juxtaglomerular apparatus could be observed in the removed kidneys of
ADPKD patients, referring to the involvement of RAAS activity (45). The vast majority of
our ADPKD patients were treated with RAAS inhibitors, and thus we have no data to draw
any conclusion on this.
Kocyigit et al. (24) showed relationship between early arterial stiffness and inﬂam-
matory biomarkers in normotensive ADPKD patients by showing that arterial stiffness was
increased prior to the onset of hypertension or renal function decline, and interleukin-6,
tumor necrosis factor-α, and C-reactive protein levels were all signiﬁcant predictors of
PWV. This ﬁnding indicates the presence of low-grade, systemic inﬂammatory processes
that contribute to early arterial damage and thus to the resultant arterial stiffness in
ADPKD (24).
Renal and CV outcome and increased vascular stiffness
Epidemiologic longitudinal studies have clearly demonstrated that arterial stiffness has an
independent predictive value of CV outcomes in different populations (10, 26, 27, 51).
Blacher et al. (4) found that every 1 m/s elevation of PWV increased the CV and total
mortality by 14% in ESRD. Recently, Nowak et al. (40) reported that impaired endothelium-
dependent vasodilation and enhanced arterial stiffness were independent predictors of CV
events and mortality in children and young adults with ADPKD having preserved renal
function.
Table IV. The prognostic role of metabolic syndrome in association with primary and secondary endpoints in
ADPKD (Cox regression analysis)
Hazard
ratio 95% CI Coefﬁcient SE Z-statistic p value
Primary, combined
endpoints
2.046 0.949 4.410 0.716 0.391 1.827 0.067
Cardiovascular
endpoints
4.676 1.239 17.641 1.542 0.677 2.277 0.022*
Renal endpoints 1.065 0.389 2.916 0.063 0.513 0.123 0.902
CI: conﬁdence interval; SE: standard error; ADPKD: autosomal-dominant polycystic kidney disease.
*p= 0.022
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Metabolic abnormalities in ADPKD
Mao et al. (32) described in a review that a wide range of metabolic abnormalities have been
reported as part of the clinical spectrum of ADPKD. Pietrzak-Nowacka et al. (42) showed
several components of metabolic syndrome, such as hypertension, abdominal obesity, and
higher fasting blood glucose level in ADPKD. However, there remains uncertainty as to the
consistency of these ﬁndings in different populations and the precise underlying molecular
mechanisms that link them to the genetic defects in ADPKD (32).
In his reviews (11, 12), Ecder also calls attention to the early occurrence
of CV complications in ADPKD and recommends multifactorial risk-reduction (hyper-
tension, obesity, dyslipidemia, and smoking). Particularly, the most important is early
detection of hypertension to prevent vascular complications and the use of angiotensin-
converting enzyme inhibitor (ACEI) treatment to reduce CV events (11, 12, 35, 36).
In this study, 84% of ADPKD patients take ACEI or angiotensin-receptor blocking agent
to treat their hypertension, which could positively alter the SIDVP and the CV outcome of
the patients (31).
Methods for measurement of arterial stiffness
Arterial stiffness can be measured by several methods (38). In this follow-up study, we
applied ﬁnger photoplethysmography method using the Pulse Trace System to measure
SIDVP. SIDVP is a composite parameter inﬂuenced by ﬂexibility of the large central arteries as
well as by reﬂective properties of the peripheral arteries. The usefulness of the SIDVP was
already successfully tested in healthy individuals and in patients with hypertension, diabetes
mellitus, coronary arterial disease, and ESRD (3, 21). Furthermore, SIDVP helped in risk
stratiﬁcation of both hypertensive and apparently healthy people with different CV risk
factors (8, 18). However, the method was not used before our previous (22) and present
studies for the stiffness measurement of ADPKD patients.
Study limitations
The results of this study demonstrated that arterial stiffness measured by ﬁnger photo-
plethysmography has a prognostic value, although occasionally there are difﬁculties in
registering the digital pulse volume. It may be problematic in some cases, mostly in elder
patients to conﬁdently separate systolic and reﬂective waves, and thus assess the SI.
Atrial ﬁbrillation and frequent atrial and ventricular ectopic activities could also limit the
detection of correct pulse curves. We estimated and not measured the renal function;
however, the use of eGFR is widely accepted throughout the literature. The study may be
weakened by the low number of our cases. It is conceivable that study follow-up period
was rather short to be sufﬁcient to prove the difference in the occurrence of CV events
and renal failure.
Conclusions
We conclude that increased arterial stiffness predicts the occurrence of ESRD and CV
endpoints in ADPKD, particularly, in patients with multiple CV risk factors; hence, early
measurement of arterial stiffness can be recommended. Further studies are required with DVP
(arterial SI) measurements using the Pulse Trace System to get this method widely accepted
for predicting the renal progression and CV events in CKD.
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